YZi Labs has publicly warned CEA Industries (Nasdaq: BNC) about a possible Nasdaq delisting. On February 13, investment partner Alex Odagiu released a sharp letterYZi Labs has publicly warned CEA Industries (Nasdaq: BNC) about a possible Nasdaq delisting. On February 13, investment partner Alex Odagiu released a sharp letter

YZi Labs Warns CEA Industries of Nasdaq Delisting Risk

2026/02/13 19:03
3 min read

YZi Labs has publicly warned CEA Industries (Nasdaq: BNC) about a possible Nasdaq delisting. On February 13, investment partner Alex Odagiu released a sharp letter to the company’s board. He said CEA has not held an annual shareholder meeting for more than 400 days. The last meeting took place on December 17, 2024. The letter claims the board changed its fiscal year to delay the next meeting. YZi argues this move could violate Nasdaq rules and put the listing at risk. It demanded an immediate meeting date or further action.

Proxy Fight Heats Up Between YZi Labs and the Board

This letter comes during a wider proxy battle. YZi Labs has been trying to change the board’s structure since late 2025. It filed a consent solicitation to expand the board from five to seven seats. The group also proposed new director nominees tied to YZi.

YZi Labs says the company needs stronger leadership to unlock value. It points to CEA Industries’ strategy around BNB linked treasury and asset management plans. The firm holds about 2.15 million shares directly. It also controls large warrant positions, though ownership caps limit exercise rights. The conflict has grown more public in recent weeks. Both sides now accuse each other of poor governance and secrecy.

Board Moves and Counter Accusations

CEA’s board has already taken defensive steps. It adopted a stockholder rights plan, often called a poison pill. The board also amended its bylaws earlier in 2026. YZi Labs claims these moves restrict shareholder influence. Meanwhile, CEA Industries has pushed back. It accused YZi and partner firms of hidden agreements tied to asset deals. YZi denied those claims. It said the agreements ended in December 2025 and were properly disclosed. This back and forth has created confusion among investors. Each side now paints the other as the source of the governance problems.

Nasdaq Compliance Concerns Grow

The biggest issue now centers on Nasdaq rules. Exchanges usually require companies to hold annual meetings within about a year of the fiscal cycle. YZi Labs claims the board changed its fiscal year to stretch the gap to around 16 months.

According to the letter, this tactic may still trigger a compliance review. Nasdaq can delist companies that appear to act in bad faith. Even technical loopholes may not protect them. CEA Industries’ stock has traded in a narrow range in recent weeks. But the governance dispute adds new uncertainty. A prolonged fight could hurt investor trust and the company’s listing status.

What Comes Next

The next step depends on the board’s response. YZi Labs wants an immediate announcement for the 2025 annual meeting. If that doesn’t happen, it says it will inform Nasdaq and possibly the courts. Meanwhile, the consent battle over board seats continues. Shareholders now wait for clarity. The outcome could reshape the company’s leadership and its crypto linked strategy.

The post YZi Labs Warns CEA Industries of Nasdaq Delisting Risk appeared first on Coinfomania.

Market Opportunity
ALEX Lab Logo
ALEX Lab Price(ALEX)
$0.00087
$0.00087$0.00087
0.00%
USD
ALEX Lab (ALEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.